caa a22 4500 475833155 CHVBK 20180406123846.0 cr unu---uuuuu 170329e20000201xx s 000 0 eng 10.1023/A:1007839104402 doi (NATIONALLICENCE)springer-10.1023/A:1007839104402 Mesenteric Cyclooxygenase Products After Combined Antihypertensive Treatment in Uninephrectomized SHRs [Elektronische Daten] [Francisco López-Hernández, María Montero, Rosalía Carrón] Unilateral nephrectomy in the spontaneously hypertensive rat (SHR) does not produce any change in blood pressure but does induce humoral alterations that might influence the antihypertensive action of some drugs. In this study, the antihypertensive effect of treatment (5 weeks) with placebo (control), verapamil, trandolapril, or their combination (verapamil plus trandolapril) was investigated in SHRs with half renal mass ablation, regarding the structure and function of small mesenteric arteries. Arterial pressure was followed during the period of treatment. Trandolapril and veratran returned pressure to normal, while verapamil was ineffective. Statistically significant differences in the parameters of vessel structure were not observed among groups; thus, the alterations in functionality cannot be attributed to morphologic changes. The noradrenaline-induced contraction was reduced similarly by the three treatments as compared to controls. This difference involved a higher participation of nitric oxide in the trandolapril group, while in the verapamil group the origin of the difference might be due to the abolishment of a cyclooxygenase product. Veratran retained both effects. Acetylcholine-evoked relaxation of vessels precontracted with noradrenaline was improved with treatments versus controls. The abolishment of a contracting prostanoid or an NO scavenger from the cyclooxygenase pathway, due to the treatments implemented, is probably the cause of this. Kluwer Academic Publishers, 2000 hypertension nationallicence SHR nationallicence nephrectomy nationallicence mesenteric arteries nationallicence verapamil nationallicence trandolapril nationallicence López-Hernández Francisco Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain aut Montero María Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain aut Carrón Rosalía Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/1(2000-02-01), 41-48 0920-3206 14:1<41 2000 14 10557 https://doi.org/10.1023/A:1007839104402 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007839104402 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- López-Hernández Francisco Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain aut NATIONALLICENCE 700 1- Montero María Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain aut NATIONALLICENCE 700 1- Carrón Rosalía Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/1(2000-02-01), 41-48 0920-3206 14:1<41 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer